曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常的临床研究  

Clinical trial of trimetazidine combined with atorvastatin calcium in the treatment of coronary heart disease and angina pectoris with dyslipidemia

作　　者：陈慧敏[1] 许逸飞[2] 

机构地区：[1]浙江省中医院预防保健科,杭州310006 [2]浙江省中医院心内科,杭州310006

出　　处：《中国临床药理学杂志》2016年第11期966-968,共3页The Chinese Journal of Clinical Pharmacology

基　　金：浙江省中医药科技计划基金资助项目(2009A004)

摘　　要：目的观察曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常的临床疗效及安全性。方法将60例冠心病心绞痛伴血脂异常患者随机分为对照组30例和试验组30例。对照组予以口服阿托伐他汀钙20 mg,qd;试验组在对照组的基础上,予以口服曲美他嗪20 mg,tid。比较2组患者的临床疗效、治疗前后血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平及安全性。结果治疗后,试验组的总有效率为86.67%显著高于对照组的70.00%(P<0.05)。治疗后,试验组的血清TC、TG、LDL-C水平均较对照组显著降低,HDL-C水平较对照组明显升高(P<0.05)。2组患者不良反应的发生率比较差异无统计学意义(P>0.05)。结论曲美他嗪联合阿托伐他汀钙能够显著降低冠心病心绞痛伴血脂异常患者的血脂水平,提高临床疗效,且安全性较高。Objective To evaluate the clinical efficacy and safety of trimetazidine combined with atorvastatin calcium in the treatment of coronary heart disease and angina pectoris with dyslipidemia. Methods Sixty patients of coronary heart disease with dyslipidemia were randomly divided into control group（ n = 30） and treatment group（ n = 30）. Control group was given oral atorvastatin calcium 20 mg,qd. Treatment group was received oral trimetazidine 20 mg,tid on the basis of control group.The clinical efficacy,serum total cholesterol（ TC）,triglyceride（ TG）,low density lipoprotein cholesterol（ LDL-C）,high density lipoprotein cholesterol（ HDL-C） levels before and after treatment and the incidence of adverse drug reactions were compared between two groups. Results After treatment,the total effective rate of treatment group was significantly higher than that of control group（ 86. 67% vs 70. 00%,P〈 0. 05）.After treatment,the serum levels of TC,TG and LDL- C in the treatment group were significantly lower than those in the control group,and the HDL- C level was higher than that in the control group（ P〈 0. 05）.There was no significant difference in the incidence of adverse drug reactions between two group（ P〉 0. 05）. Conclusion Trimetazidine combined with atorvastatin calcium has a definitive clinical efficacy and safety for the treatment of coronary heart disease and angina pectoris with dyslipidemia.

关 键 词：曲美他嗪 阿托伐他汀钙 冠心病心绞痛 血脂异常 临床疗效 安全性 

分 类 号：R972[医药卫生—药品]